Han Young Eom

Han Young Eom

Auto-generated profile, based on publicly available information

Han Young Eom

Korea Inst Toxicol, Dept Adv Toxicol Res, 141 Gajeong Ro, Daejeon 34114, South Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

26 October 2023 in ACS Omega
Verified
Journal Article
Open access
HCHyun-Deok Cho
Hyun-Deok Cho
JMJung Eun Min
Jung Eun Min
MCMyeongjin Choi
Myeongjin Choi
SJSeo Yule Jeong
Seo Yule Jeong
KMKyoung-Sik Moon
Kyoung-Sik Moon
HEHan Young Eom
Han Young Eom
MicroRNA (miRNA) has recently garnered significant research attention, owing to its potential as a diagnostic biomarker and therapeutic target. Liquid chromatography-mass spectrometry (LC-MS) offers accurate quantification, multiplexing capacity, and high compatibility with various matrices. These advantages establish it as a preferred technique for detecting miRNA in biological samples. In this study, we presented an LC-MS method for directly quantifying seven miRNAs (rno-miR-150, 146a, 21, 155, 223, 181a, and 125a) associated with immune and inflammatory responses in rat whole blood. To ensure miRNA stability in the samples and efficiently purify target analytes, we compared Trizol- and proteinase K-based extraction methods, and the Trizol extraction proved to be superior in terms of analytical sensitivity and convenience. Chromatographic separation was carried out using an oligonucleotide C18 column with a mobile phase composed of N-butyldimethylamine, 1,1,1,3,3,3-hexafluoro-2-propanol, and methanol. For MS detection, we performed high-resolution full scan analysis using an orbitrap mass analyzer with negative electrospray ionization. The established method was validated by assessing its selectivity, linearity, limit of quantification, accuracy, precision, recovery, matrix effect, carry-over, and stability. The proposed assay was then applied to simultaneously monitor target miRNAs in lipopolysaccharide-treated rats. Although potentially less sensitive than conventional methods, such as qPCR and microarray, this direct-detection-based LC-MS method can accurately and precisely quantify miRNA. Given these promising results, this method could be effectively deployed in various miRNA-related applications.

31 August 2024 in Phytomedicine
Verified
Journal Article
Open access
MYMin Heui Yoo
Min Heui Yoo
HEHan Young Eom
Han Young Eom
WIWan-Jung Im
Wan-Jung Im
BLByoung-Seok Lee
Byoung-Seok Lee
KHKang-Hyun Han
Kang-Hyun Han
YKYong-Bum Kim
Yong-Bum Kim
Background: Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, remarkable advances have been made in vaccine development to reduce mortality. However, therapeutic interventions for COVID-19 are comparatively limited despite these intensive efforts. Furthermore, the rapid mutation capability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a characteristic of its RNA structure, has led to the emergence of multiple variants, necessitating a shift from a predominantly vaccine-centric approach to one that encompasses therapeutic strategies. 6 '-Hydroxy justicidin B (6 '-HJB), an arylnaphthalene lignan isolated from Justicia procumbens, a traditional Chinese medicine, is known for its antiviral properties. Hypothesis/Purpose: The aim of the present study was to assess the effectiveness and safety of 6 '-HJB against SARS-CoV-2 in order to determine its potential as a therapeutic agent against COVID-19. Methods: The efficacy of 6 '-HJB was evaluated both in vitro using Vero and Calu-3 cell lines and in vivo using ferrets. The safety assessment included toxicokinetics, safety pharmacology, and Good Laboratory Practice (GLP)-compliant toxicity evaluations following single- and repeated-dose toxicity studies in dogs. Results: The anti-SARS-CoV-2 efficacy of 6 '-HJB was evaluated through dose-response curve (DRC) analysis using immunofluorescence; 6 '-HJB demonstrated superior inhibition of SARS-CoV-2 growth and lower cytotoxicity than remdesivir. In SARS-CoV-2-infected ferret, 6 '-HJB showed efficacy comparable to that of the positive control, Truvada. Further GLP toxicity studies corroborated the safety profile of 6 '-HJB. Single-dose and 4-week repeated oral toxicity studies in Beagle dogs demonstrated minimal harmful effects at the highest dosages. The lethal dose of 6 '-HJB exceeded 2,000 mg kg-1 in Beagle dogs. Toxicokinetic and GLP safety pharmacology studies demonstrated no adverse effects of 6 '-HJB on metabolic processes, respiratory or central nervous systems, or cardiac functions. Conclusion: This research highlights both the antiviral efficacy and safety profile of 6 '-HJB, underscoring its potential as a novel COVID-19 treatment option. The potential of 6 '-HJB was demonstrated using modern scientific methodologies and standards.